Explore the words cloud of the Immune-senescence project. It provides you a very rough idea of what is the project "Immune-senescence" about.
The following table provides information about the project.
FONDAZIONE PER L'ISTITUTO ONCOLOGICO DI RICERCA (IOR)
|Coordinator Country||Switzerland [CH]|
|Total cost||2˙000˙000 €|
|EC max contribution||2˙000˙000 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2016-07-01 to 2021-06-30|
Take a look of project's partnership.
|1||FONDAZIONE PER L'ISTITUTO ONCOLOGICO DI RICERCA (IOR)||CH (BELLINZONA)||coordinator||2˙000˙000.00|
We have previously demonstrated that cellular senescence opposes tumorigenesis thereby opening up new potential opportunities for cancer treatment. Senescence and tumor immunity in cancer are tightly interconnected. Tumor-infiltrating immune cells promote the clearance of senescent tumor cells thereby contributing to the tumor suppressive function of senescence. Moreover, T lymphocytes can drive senescence in cancers by secreting different cytokines in the tumor microenvironment. We have also recently reported that GR1 myeloid cells antagonize treatment-induced senescence (TIS) and that compounds that block the tumor recruitment of GR1 cells enhance TIS. Major objective of this proposal is to characterize the immune landscape of different prostate cancer mouse models in order to develop novel treatment modalities that combine pro-senescence compounds with immunotherapy. Using proteomics and bioinformatics approaches, we will assess how the genetic background of prostate tumors, shapes the tumor microenvironment and immune response during TIS. Next, we will define the mechanisms that regulate the recruitment and activation of myeloid derived suppressive cells, macrophages and B-lymphocytes in Pten deficient prostate tumors by focusing on a novel class of secreted factors identified in these tumors. We will also assess in vivo whether the secretome of tumor cells can transmit senescence to TILs and compounds that interfere with the secretome can prevent immunosenescence. Finally, we will develop monoclonal antibodies directed towards senescent tumors cells that we will use as diagnostic and therapeutic tools. These antibodies will be used as biomarkers to detect senescent tumor cells in prostate cancers and will be tested in pre-clinical trials to assess whether they improve tumor clearance during TIS. Our findings will form the basis for future clinical trials in prostate cancer patients.
Work performed, outcomes and results: advancements report(s)
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNE-SENESCENCE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "IMMUNE-SENESCENCE" are provided by the European Opendata Portal: CORDIS opendata.
Targeting Meniscus Degradation in OsteoarthritisRead More
Pro-tumorigenic effects of TGFb - elucidation of mechanisms and development of selective inhibitorsRead More
Property and Democratic Citizenship: The Impact of Moral Assumptions, Policy Regulations, and Market Mechanisms on Experiences of EvictionRead More